Inspire Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Inspire Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27	Closed	-$2K	–	170
2020 Q4	$2K	Buy	+27	New	+$2.14K	﹤0.01%	672

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Inspire Advisors's BMRN Position: Q1 2021 in Review

Inspire Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 27 shares — an estimated $2K sold.

Inspire Advisors first reported a position in BMRN in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Inspire Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 27 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $2K.
Inspire Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Inspire Advisors's BioMarin Pharmaceuticals position peaked at $2K in Q4 2020.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.